Creation of Big Data repositories is now emphasized at virtually all research institutions and the NIH, but the number of publications describing patient outcomes from these sources appears modest.1 Why is this so; what factors limit what should be a hugely productive resource, and how can we improve the impact of this use of Big Data? Why does this issue require greater physician engagement and understanding to solve? The integration of clinical, laboratory, and financial data is required to describe disease and treatment outcomes as well as treatment value.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
